| Nr. Crt. | Nume | Status | Locatie |
| 1 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) | Activ, inca nu recruteaza | Centrul de Oncologie Sf. Nectarie SRL Craiova, Dolj, Romania, 200347 S.C. R.T.C. Radiology Therapeutic Center S.R.L. Otopeni, Ilfov, Romania, 075100 SC Oncopremium Team SRL Baia Mare, Maramureș, Romania, 430291 Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328 Spitalul Clinic Filantropia Bucuresti, Romania, 011171 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca Cluj-Napoca, Romania, 400015 Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta Constanta, Romania, 900591 |
| 2 | Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) | In curs de recrutare | Local Institution Not yet recruiting Bucharest, Romania, 011171 Contact: Site 0029 Local Institution Not yet recruiting Bucuresti, Romania, 022328 Contact: Site 0025 Local Institution Not yet recruiting Craiova, Romania, 200347 Contact: Site 0028 Local Institution Not yet recruiting Floresti, Romania, 407280 Contact: Site 0027 Local Institution Not yet recruiting Suceava, Romania, 720237 Contact: Site 0026 |
| 3 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1) | Activ, inca nu recruteaza | Novartis Investigative Site Floresti, Cluj, Romania, 407280 Novartis Investigative Site Bucuresti, Romania, 011171 Novartis Investigative Site Bucuresti, Romania, 030463 Novartis Investigative Site Craiova, Romania, 200347 Novartis Investigative Site Iasi, Romania, 700483 Novartis Investigative Site Timisoara, Romania, 300219 |
| 4 | A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA) | Activ, inca nu recruteaza | County Hospital Alba; Oncology Alba Iulia, Romania, 510073 „Filantropia” Clinical Hospital; Gynecological Oncology Bucharest, Romania, 011191 Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology Cluj-Napoca, Romania, 400006 Centrul de OncologieSfantulNectarie Craiova, Romania, 200347 Oncomed SRL Timisoara, Romania, 300239 |
| 5 | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | Activ, inca nu recruteaza | S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948 Craiova, Dolj, Romania, 200347 lnstitutul Oncologic Trestiore /ID# 124943 Bucharest, Romania, 022328 Spitalul Clinic Judetean de Urgenta /ID# 124945 Cluj, Romania, 400006 Oncomed SRL /ID# 127598 Timisoara, Romania, 300239 |
| 6 | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | In curs de recrutare | „Filantropia” Clinical Hospital; Gynecological Oncology Not yet recruiting Bucharest, Romania, 011191 Institute of Oncology „Prof. Dr. I. Chiricuta” Not yet recruiting Cluj-Napoca, Romania, 400015 Oncology Center Sf. Nectarie Not yet recruiting Craiova, Romania, 200347 Centrul de OncologieOncohelp Not yet recruiting Timisoara, Romania, 300239 |
| 7 | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer | Activ, inca nu recruteaza | Center of Oncology Euroclinic Bucharest, Romania Oncology Center Sf Nectarie Caracal, Romania Cluj County Clinical Emergency Hospital, Clinical Department of Medical Oncology Cluj-Napoca, Romania Oncology Institute „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania Oncology Center Oncolab Craiova Craiova, Romania |
| 8 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | Activ, inca nu recruteaza | Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Cluj Clinical County Hospital; Oncology Dept Cluj-Napoca, Romania, 400006 Regional Institute of Oncology Iasi Iasi, Romania, 700483 |
| 9 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Activ, inca nu recruteaza | Emergency University Bucharest Hospital; Oncology Department Bucharest, Romania, 050098 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Inst. Cluj-Napoca; Cancer Dept Cluj-Napoca, Romania, 400015 Euroclinic Center of Oncology SRL Iasi, Romania, 700106 |
| 10 | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. | Activ, inca nu recruteaza | Research Site Braila, Romania, 810325 Research Site Craiova, Romania, 200347 Research Site Onesti, Romania, 601048 Research Site Timisoara, Romania, 300239 |
| 11 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | In curs de recrutare | „Filantropia” Clinical Hospital; Gynecological Oncology Recruiting Bucharest, Romania, 011191 Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Recruiting Bucuresti, Romania, 022328 Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; OncologieMedicala Recruiting Cluj Napoca, Romania, 400015 Centrul de OncologieSfantulNectarie Recruiting Craiova, Romania, 200347 |
| 12 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | Activ, inca nu recruteaza | Spitalul Clinic CF nr.2 Bucuresti Bucharest, Romania, 011464 Spitalul Municipal Ploiesti Ploiesti, Romania, 100337 SpitalulJudetean de Urgente „Sf. IoancelNou” Suceava, Romania, 720237 Spitalul Clinic JudeteanMures TgMures, Romania, 540142 |
| 13 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy | Activ, inca nu recruteaza | Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department Bucuresti, Romania, 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347 Euroclinic Center of Oncology SRL Iasi, Romania, 700106 |
| 14 | PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer | Activ, inca nu recruteaza | Prof. Dr. I. Chiricuta Oncology Institute Cluj-Napoca, Romania Sf. Nectarie SRL Oncologie Medical Center Craiova, Romania Center of Oncology Euroclinic Iași, Romania |
| 15 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) | Activ, inca nu recruteaza | Prof. Dr. I. Chiricuta Institute of Oncology Active, not recruiting Cluj Napoca, Romania, 400015 Centrul de OncologieSfantulNectarie Craiova, Romania, 200347 Active, not recruiting |
| 16 | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | Activ, inca nu recruteaza | Research Site Bucharest, Romania, 013811 Research Site Bucuresti, Romania, 011171 Research Site Bucuresti, Romania, 030171 Research Site Cluj Napoca, Romania, 400015 Research Site Cluj-Napoca, Romania, 400015 |
| 17 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer | Activ, inca nu recruteaza | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician. |
| 18 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Activ, inca nu recruteaza | Novartis Investigative Site Bucharest, Romania, 050098 Novartis Investigative Site Bucuresti, Romania, 022328 Novartis Investigative Site Timisoara, Romania, 300239 |
| 19 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | Activ, inca nu recruteaza | Novartis Investigative Site Bucharest, Romania, 022328 Novartis Investigative Site Bucharest, Romania, 050098 Novartis Investigative Site Bucuresti, Romania, 022328 Novartis Investigative Site Cluj-Napoca, Romania, 400015 Novartis Investigative Site Iasi, Romania, 700106 |
| 20 | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | Activ, inca nu recruteaza | Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347 |
| 21 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | Activ, inca nu recruteaza | Oncomed SRL Timisoara, Romania, 300239 |
| 22 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) | In curs de recrutare | Novartis Investigative Site Craiova, Dolj, Romania, 200347 Novartis Investigative Site Craiova, Dolj, Romania, 200535 Novartis Investigative Site Bucuresti, Romania, 010991 Novartis Investigative Site Bucuresti, Romania, 011171 Novartis Investigative Site Cluj-Napoca, Romania, 400124 Novartis Investigative Site Iasi, Romania, 700106 Novartis Investigative Site Timisoara, Romania, 300239 |
| 23 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | Inca nu recruteaza | Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj, Romania, 400015 Contact: Principal Investigator Onco Clinic Consult SA Craiova, Dolj, Romania, 200103 Contact: Principal Investigator Centrul de Oncologie Sfantu Nectarie Craiova, Dolj, Romania, 200347 Contact: Principal Investigator Institutul Oncologic Bucuresti IOB Bucharest, Romania, 22328 Contact: Principal Investigator |
| 24 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | In curs de recrutare | Research Site Recruiting Bucharest, Romania, 022328 Research Site Recruiting Bucharest, Romania, 022338 Research Site Recruiting Bucharest, Romania, 030171 Research Site Recruiting Cluj Napoca, Romania, 400015 Research Site Recruiting Iasi, Romania, 700483 Research Site Recruiting Ploiesti, Romania, 100337 Research Site Recruiting Timisoara, Romania, 300239 |
(Visited 464 times, 1 visits today)